Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orchard Plans EU Submission For GSK-Originated MLD Gene Therapy

Executive Summary

Orchard is aiming to get its second autologous gene therapy on the market next year, with a European filing for MLD and a BLA to follow.

You may also be interested in...



Genespire Glides Into Gene Therapy Space

Milan, Italy is a hotspot in Europe for gene therapy research, and the European VC Sofinnova Partners is backing the latest start-up aimed at metabolic and primary immunodeficiencies.

Orchard To Use Divested GSK Rare Disease Gene Therapies To Grow Globally

Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.

Dinosaur Among The Unicorns: L'Oreal Talks Beauty Tech Innovation At VivaTech 2022

L’Oreal Group’s CEO referred VivaTech 2022 attendees to Yves Saint Laurent Beauty Scent-Sation, an electroencephalography-based headset that reads consumers’ emotional responses to different scent families, as an example of the firm’s beauty tech innovation that is personalizing the consumer experience, matching consumers with products, and distinguishing L’Oreal as a … err … “T-unicorn.”

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC124984

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel